Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Solventum beats quarterly estimates on strong demand for surgical products February 26, 20269:43 PM UTCUpdated ago By Reuters Sign up here. Solventum's MedSurg business, which sells wound dressings and surgical equipment, accounts for more than half the company's revenue. Sales in the segment rose 5.2% from a year earlier to $1.24 billion during the quarter. The company's quarterly revenue cam ...

Stryker Corporation (NYSE:SYK) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 2, the price target on Stryker Corporation (NYSE:SYK) was raised from $462 to $469 by Barclays. The firm reaffirmed its Overweight rating on the stock that yields a revised upside potential of more than 23%. Without any deviations from the model, the firm believes there is significant upside for the company’s growth estimates for 2026. Stryker Corporation (SYK) Gains Strength From ...

Group 1 - Stryker Corporation (NYSE:SYK) is recognized as one of the top 12 Medical Devices stocks to invest in according to Hedge Funds [1] - Matthew O'Brien from Piper Sandler has reiterated an Overweight rating on Stryker with a price target of $420, indicating over 17% upside potential for investors [1][2] - The company is introducing a new handheld orthopedic robot, Mako RPS, which is expected to enhance its market presence in lower-cost segments, including ambulatory surgical centers and select international markets [2] Group 2 - Evercore ISI has maintained an Outperform rating on Stryker while adjusting the target price from $405 to $390, citing recoveries in end markets and anticipated healthy capital expenditures in the medical technology sector for 2026 [3] - Stryker operates in two segments: MedSurg & Neurotechnology and Orthopaedic, focusing on innovative products to improve patient outcomes [4]

Group 1 - Bausch + Lomb Corporation (NYSE:BLCO) has seen an 8.59% increase in share price recently, but Wall Street maintains a cautious outlook on the stock [1] - The company presented its growth strategy on November 13, targeting a compound annual growth rate (CAGR) of 5% to 7% through 2028, driven by product launches and overall growth [2] - Bausch + Lomb aims for an adjusted EBITDA of around 23% by 2028 while reaffirming its guidance for 2025 [2] Group 2 - Analysts have mixed ratings on Bausch + Lomb, with Barclays reiterating a Hold rating and a price target of $17, while Bank of America Securities maintains a Sell rating with a price target of $13 [3] - Concerns have been raised regarding the company's optimistic growth projections, which some analysts believe reflect only a best-case scenario and may be overestimated [4] - The growth targets are heavily reliant on execution rather than innovation, increasing the associated risk [4] Group 3 - Bausch + Lomb is recognized as a leading company in eye health, focusing on products such as contact lenses, pharmaceuticals, and surgical equipment [5]

Core Viewpoint - Stryker Corporation is a leading medical technology company set to announce its fiscal third-quarter earnings for 2025, with analysts expecting a positive earnings report and growth in EPS over the coming years [1][2][3]. Financial Performance - Analysts anticipate Stryker to report a profit of $3.14 per share for Q3 2025, reflecting a 9.4% increase from $2.87 per share in the same quarter last year [2]. - For the full fiscal year 2025, EPS is expected to be $13.50, a 10.8% increase from $12.19 in fiscal 2024, with further growth projected to $14.95 in fiscal 2026, representing a year-over-year rise of 10.7% [3]. Stock Performance - Stryker's stock has underperformed compared to the S&P 500 Index, which gained 13.5% over the past 52 weeks, while Stryker shares only increased by 2.2% during the same period [4]. - The stock also lagged behind the Health Care Select Sector SPDR Fund, which experienced a 7.2% decline [4]. Competitive Landscape - The company's underperformance is attributed to increased competition from Zimmer Biomet, Johnson & Johnson, and Medtronic, particularly in the robotic orthopedics segment, along with macroeconomic pressures such as inflation and wage pressures affecting margins [5]. Analyst Sentiment - The consensus among analysts is moderately bullish, with a "Moderate Buy" rating overall. Out of 28 analysts, 18 recommend a "Strong Buy," 2 suggest a "Moderate Buy," and 8 advise a "Hold" [7]. - The average analyst price target for Stryker is $434.48, indicating a potential upside of 17.7% from current levels [7].